Long-term, repeated doses of intravenous autologous mesenchymal stem cells for a patient with Parkinson's disease: a case report

Ridhima Vij; Alan Prossin; Mallika Tripathy; Hosu Kim; Hyeonggeun Park; Thanh Cheng; Djamchid Lotfi; Donna Chang

doi:10.3389/fneur.2023.1257080

Long-term, repeated doses of intravenous autologous mesenchymal stem cells for a patient with Parkinson's disease: a case report

Front Neurol. 2023 Sep 27:14:1257080. doi: 10.3389/fneur.2023.1257080. eCollection 2023.

Authors

Ridhima Vij¹, Alan Prossin², Mallika Tripathy², Hosu Kim³, Hyeonggeun Park³, Thanh Cheng¹, Djamchid Lotfi¹, Donna Chang^{1

3}

Affiliations

¹ Hope Biosciences Research Foundation, Sugar Land, TX, United States.
² McGovern Medical School at UTHealth Houston, TX, United States.
³ Hope Biosciences, Sugar Land, TX, United States.

Abstract

Parkinson's disease (PD) is a neurodegenerative disease that involves the loss of dopaminergic neurons in the substantia nigra pars compacta of the basal ganglia. Clinically, patient presentation involves a combination of motor and non-motor symptoms characterized by progressive worsening over time and significant decreases in overall quality-of-life. Despite there being no fully restorative cure for PD, Mesenchymal Stem Cell (MSC) therapy offers promising therapeutic potential. Here, we report a case of a 77-year-old female, living with idiopathic Parkinson's Disease for over 17 years. The patient received multiple infusions of autologous Hope Biosciences adipose-derived MSCs (HB-adMSCs). A total of 26 infusion treatments of HB-adMSCs were administered over the course of ~2 years that resulted in marked improvements in her typical Parkinsonian symptoms, as demonstrated by the decreases in her UPDRS (Unified Parkinson's Disease Rating Scale) scores. Changes in clinical scores mirrored concurrent changes in regional brain metabolism as quantified by FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography), compared to baseline. Long-term, multiple infusions of HB-adMSCs were safely tolerated by the patient without any serious adverse events. Further research is needed to evaluate the safety and efficacy of HB-adMSC therapy for the treatment of PD patients.

Keywords: Parkinson's disease; adipose derived; autologous; case report; mesenchymal stem cells.

Publication types

Case Reports

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded in whole by Hope Biosciences Research Foundation and Hope Biosciences LLC provided the investigational drug.